Anti-Tumour Effects of Exosomes in Combination with Cyclophosphamide and Polyinosinic

Abstract

We examined the anti-tumour activity of exosomes derived from dendritic cells (DCs) in combination with cyclophosphamide (CTX) and polyinosinic–polycytidylic acid sodium salt (poly I:C). DCs were pulsed with L1210 lymphocytic leukaemia cell antigen and lipopolysaccharide. The exosomes that the DCs secreted were purified. In vitro, the anti-tumour activity of exosomes was assessed by measuring their ability to induce spleen cell proliferation and the extent to which they induced spleen cells to kill L1210 cells. Poly I:C was able to induce DC maturation. DC-derived exosomes stimulated spleen cell proliferation and enhanced the cytotoxic effects of spleen cells in vitro. DC-derived exosomes, in combination with CTX and poly I:C, suppressed L1210 tumour growth in vivo and gave the greatest prolongation of survival time in tumour-bearing DBA2 mice. These findings suggest that this combination of a tumour vaccine, a conventional anti-cancer agent and a promoter of DC maturation might be a useful anti-cancer therapy.

Keywords

Cyclophosphamide Poly I:C Anti-cancer agents Cancer Tumour immunology Regulatory T cells Exosomes Toll-like receptor

References

Johnstone

Adam

Hammond

: Vesicle formation during reticulocyte maturation. J Biol Chem 1981; 262: 9412–9420.

Heijnen

Schiel

Fijnheer

: Activated platelets release two types of membrane vesicles: Microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and α-granules. Blood 1999; 94: 3791–3799.

Raposo

Nijman

Stoorvogel

: B lymphocytes secrete antigen-presenting vesicles. J Exp Med 1996; 183: 1161–1172.

Blanchard

Lankar

Faure

: TCR activation of human T cells induces the production of exosomes bearing the TCR/CD3/ς complex. J Immunol 2002; 168: 3235–3241.

Raposo

Tenza

Mecheri

: Accumulation of major histocompatibility complex class II molecules in mast cell secretory granules and their release upon degranulation. Mol Biol Cell 1997; 8: 2631–2645.

Van Niel

Raposo

Candalh

: Intestinal epithelial cells secrete exosome-like vesicles. Gastroenterology 2001; 121: 337–349.

Zitvogel

Regnault

Lozier

: Eradication of established murine tumors using a novel cell-free vaccine: Dendritic cell-derived exosomes. Nat Med 1998; 4: 594–600.

Théry

Duban

Segura

: Indirect activation of naive CD4+ T cells by dendritic cell-derived exosomes. Nat Immunol 2002; 3: 1156–1162.

Kadowaki

Antonenko

: Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 2001; 194: 863–869.

10.

Segura

Amigorena

Théry

: Mature dendritic cells secrete exosomes with strong ability to induce antigen-specific effector immune responses. Blood Cells Mol Dis 2005; 35: 89–93.

11.

Taylor

Harris

Babayan

: CTLA-4 and CD4+CD25+ regulatory T cells inhibit protective immunity to filarial parasites in vivo. J Immunol 2007; 179: 4626–4634.

12.

Loddenkemper

Schernus

Noutsias

: In situ analysis of FOXP3+ regulatory T cells in human colorectal cancer. J Transl Med 2006; 4: 52.

13.

Taieb

Chaput

Schartz

: Chemoimmunotherapy of tumors: Cyclophosphamide synergizes with exosome based vaccines. J Immunol 2006; 176: 2722–2729.

14.

Chen

Dehm

Bonham

: DNA array and biological characterization of the impact of the maturation status of mouse dendritic cells on their phenotype and antitumor vaccination efficacy. Cell Immunol 2001; 214: 60–71.

15.

Lovrien

Matulis

: Assays for total protein. Curr Protoc Microbiol 2005 Oct; Appendix 3: Appendix 3A.

16.

Escudier

Dorval

Chaput

: Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: Results of the first phase I clinical trial. J Transl Med 2005; 3: 10.

17.

Morse

Garst

Osada

: A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med 2005; 3: 9.

18.

André

Chaput

Schartz

: Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells. J Immunol 2004; 172: 2126–2136.

19.

Morelli

Larregina

Shufesky

: Endocytosis, intracellular sorting, and processing of exosomes by dendritic cells. Blood 2004; 104: 3257–3266.

20.

Adikari

Pettersson

Soderstrom

: Interleukin-10-modulated immature dendritic cells control the proinflammatory environment in multiple sclerosis. Scand J Immunol 2004; 59: 600–606.

21.

Cranmer

Hersh

: The role of the CTLA4 blockade in the treatment of malignant melanoma. Cancer Invest 2007; 25: 613–631.

22.

Kadowaki

Antonenko

: Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 2001; 194: 863–869.

23.

Sutmuller

Garritsen

Adema

: Regulatory T cells and toll-like receptors: Regulating the regulators. Ann Rheum Dis 2007; 66: 91–95.

24.

Sakaguchi

Yamaguchi

Nomura

: Regulatory T cells and immune tolerance. Cell 2008; 133: 775–787.

25.

Maki

: Future directions for immunotherapeutic intervention against sarcomas. Curr Opin Oncol 2006; 18: 363–368.

Anti-Tumour Effects of Exosomes in Combination with Cyclophosphamide and Polyinosinic–Polycytidylic Acid

Abstract

Keywords

References